Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Buzz on the Bullboards: Market Movers in Energy, Tech and Health

‘Tis the season for second-quarter financial results. Last week Baytex Energy Corp. ( TSX:BTE , Forum ) , a Calgary-based oil and gas company that operates in Canada and the United States , released its Q2 2021 financial results for the quarter e...
Jocelyn Aspa | August 4, 2021 |

XPhyto: Proof of Concept for Mescalin Synthesis

It’s become a much talked-about story on both sides of the Atlantic. XPhyto Therapeutics Corp. ( CSE: XPHY ) (FSE: 4XT) (OTCQB: XPHYF) has earned considerable media coverage in recent months due to its expansion into the development of psychedelic d...
Marc Davis | June 9, 2021 |

Buzz on the Bullboards: Cancer Detection of the Future … Today

(Image via StageZero Life Sciences Ltd.) Even though there is a wide buffet of rich investing opportunities out there that are of high appeal to serious investors and small-cap opportunists in the current market, COVID-19 movements still take the cake. Over the ...
Stockhouse Editorial | April 14, 2021 |

From COVID to Nicotine Treatments, this Bio Stock is One to Watch

(Image via Lexaria Bioscience Corp.) There’s no shortage of excitement over potential COVID-19 vaccines. Just looking at the response to news around these developments is evidence of that, and one Company is working on a transformative, patented tech...
Stockhouse Editorial | December 1, 2020 |

Buzz on the Bullboards – The Next Great Oil Frontier?

(Image via Crescent Point Energy.) September is often seen as a “fresh start” for the markets, like a new year on the stock exchange, but this party was met with a serious hangover in the shape of poor share performances that only just recently b...
Stockhouse Editorial | September 16, 2020 |

Q&A with Cerro de Pasco Resources: Newly appointed CTO on the value of sustainable mining

If the World Economic Forum is any authority on the subject, the mining and metals sector – in its inherent connection to almost all industry value chains – “is an integral part of any foreseeable economy and society.” To that end, and with an ever-growi...
Oliver Gray | July 9, 2020 |

Akero Therapeutics Shares Rise on Positive Data from Phase 2a NASH Study

Akero Therapeutics shares traded 28% higher and established a new 52-week high after the company reported that it recorded positive histological data across all Efruxifermin dosage groups in its Phase 2a BALANCED Study in NASH patients. Clinical-stage biotechnology...
Streetwise Reports | July 2, 2020 |

Arbutus Biopharma Trades 25% Higher on Phase 1 Hepatitis B Results

Shares of Arbutus Biopharma traded higher after the company reported significant and continuous reduction in HBsAg in 12 chronic hepatitis B subjects using 60 mg dosage of its AB-729 drug. Clinical-stage biopharmaceutical company Arbutus Biopharma Corp. (ABUS:NASD...
Streetwise Reports | May 20, 2020 |

Biopharma Reports Consistent 'Phase 2 Liver Fat (NASH and NAFLD) Results'

The new data are reviewed and updates are provided on Can-Fite BioPharma's other clinical studies, including one for COVID-19, in this Dawson James research report. In an April 20 research note, Dawson James analyst Jason Kolbert wrote that results from Can...
Streetwise Reports | April 23, 2020 |

Underowned and Underloved

Back in the Dark Ages, before cellular phones and the Internet, I was studying to complete the Ontario Securities course one afternoon when I came across the part discussing "asset allocation" and "portfolio construction." This section covered the recommended mix of bonds...
Streetwise Reports | April 14, 2020 |
1 2 3 4